November 26, 2015
Sinclair IS Pharma going aesthetic
Sinclair IS Pharma plc will sell its non-aesthetics business to Alliance Pharma plc for £132m
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
November 26, 2015
NICE recommends drugs to treat 4 different medical conditions
The National Institute for Health and Care Excellence (NICE) has published its final recommendations on whether six different drug treatments…
November 26, 2015
LEO Pharma appoints Svend Andersen EVP head of Europe+
LEO Pharma has named Svend Andersen as incoming EVP, Head of Region EUROPE+, who will assume the position of Executive Vice President, Head of Region EUROPE+, on January 1, 2016. He will join LEO Pharma’s Executive Leadership Team and report directly to the CEO.
November 26, 2015
Teva to receive global development and commercial rights to Hemtares’ novel CGRP antagonists
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.
November 25, 2015
U.S. politicians slam tax-avoiding Pfizer-Allergan deal
U.S. politicians condemned Pfizer Inc’s deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely.
November 24, 2015
Pfizer to buy Allergan in $160 billion deal
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion (£106 billion) to slash its U.S. tax bill, rekindling a fierce political debate over the financial manoeuvre.
November 24, 2015
Tiziana Life Sciences places banker to its Board
Tiziana Life Sciences plc, the clinical stage biotechnology company focused on oncology and immunology related drugs, has appointed a banker Willy Simon as a non-executive director.
November 24, 2015
Futura Medical’s two painkillers cleared path for Europe
Futura Medical, a transdermal technology specialist, has received by an European regulator clarity on the regulatory pathways for its two topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen).
November 24, 2015
Abzena buys US-based contract chemistry specialist TCRS for $15M
Abzena plc will buy Philadelphia-based The Chemistry Research Solution LLC (TCRS), a specialist contract chemistry and bioconjugation company, specialized in producing and analyzing antibody drug conjugates (DACs), for $15 million
November 24, 2015
Advanced Oncotherapy names CERN’s Stephen Myers new Chairman of ADAM
Advanced Oncotherapy, the developer of proton therapy systems for cancer treatment, has appointed Professor Stephen Myers OBE, Head of Medical Applications at CERN, as Executive Chairman of its subsidiary ADAM S.A.